Symbols / XFOR $3.56 -3.52%
XFOR Chart
About
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical trial to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor with or without stable doses of G-CSF in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications; and with Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand. The company is headquartered in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 311.27M |
| Enterprise Value | 266.44M | Income | -95.09M | Sales | 33.98M |
| Book/sh | 2.45 | Cash/sh | 1.40 | Dividend Yield | — |
| Payout | 0.00% | Employees | 143 | IPO | — |
| P/E | — | Forward P/E | -3.08 | PEG | — |
| P/S | 9.16 | P/B | 1.45 | P/C | — |
| EV/EBITDA | -2.95 | EV/Sales | 7.84 | Quick Ratio | 5.27 |
| Current Ratio | 5.65 | Debt/Eq | 125.54 | LT Debt/Eq | — |
| EPS (ttm) | -8.92 | EPS next Y | -1.16 | EPS Growth | — |
| Revenue Growth | 215.20% | Earnings | 2026-03-24 | ROA | -33.54% |
| ROE | -156.87% | ROIC | — | Gross Margin | 83.24% |
| Oper. Margin | -12.81% | Profit Margin | -279.86% | Shs Outstand | 87.44M |
| Shs Float | 61.12M | Short Float | 3.96% | Short Ratio | 6.73 |
| Short Interest | — | 52W High | 9.69 | 52W Low | 1.35 |
| Beta | 0.46 | Avg Volume | 590.80K | Volume | 441.39K |
| Target Price | $10.00 | Recom | Strong_buy | Prev Close | $3.69 |
| Price | $3.56 | Change | -3.52% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.00
Mean price target
2. Current target
$3.56
Latest analyst target
3. DCF / Fair value
$-13.98
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.56
Low
$5.00
High
$13.00
Mean
$10.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-09 | init | Guggenheim | — → Buy | $12 |
| 2025-12-05 | main | Stifel | Buy → Buy | $10 |
| 2025-11-10 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-08-29 | main | Stifel | Buy → Buy | $9 |
| 2025-08-13 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-05-02 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-03-27 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2025-03-26 | reit | Cantor Fitzgerald | Overweight → Overweight | $3 |
| 2025-02-07 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2025-01-14 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2024-11-14 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2024-11-14 | main | Stifel | Buy → Buy | $4 |
| 2024-06-28 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-05-31 | reit | Cantor Fitzgerald | Overweight → Overweight | $5 |
| 2024-04-30 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-03-22 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2023-12-12 | down | B. Riley Securities | Buy → Neutral | $1 |
| 2023-08-11 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2023-05-17 | main | Stifel | Buy → Buy | $5 |
| 2023-05-05 | reit | HC Wainwright & Co. | — → Buy | $3 |
- X4 Pharmaceuticals, Inc. $XFOR Shares Acquired by Kingdon Capital Management L.L.C. - MarketBeat Mon, 16 Mar 2026 11
- XFOR Exceeds Revenue Expectations and Advances Key Trials - GuruFocus ue, 17 Mar 2026 12
- $XFOR stock is up 15% today. Here's what we see in our data. - Quiver Quantitative Mon, 22 Dec 2025 08
- X4 Pharma (NASDAQ: XFOR) closes $155.3M offering; underwriters' option fully exercised - Stock Titan Mon, 27 Oct 2025 07
- X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia (NASDAQ:XFOR) - Seeking Alpha Mon, 01 Dec 2025 08
- X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) largest shareholders are individual investors with 52% ownership, institutions own 31% - Yahoo Finance Sun, 18 Jan 2026 08
- All you need to know about X4 Pharmaceuticals (XFOR) rating upgrade to buy - MSN Sat, 14 Mar 2026 07
- XFOR's Strong Financial Position Secures Operations Through 2028 - GuruFocus ue, 17 Mar 2026 12
- X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention - 24/7 Wall St. Mon, 09 Mar 2026 15
- Rosalind Advisors Inc. Makes New Investment in X4 Pharmaceuticals, Inc. $XFOR - MarketBeat Fri, 13 Mar 2026 10
- X4 Pharmaceuticals (NASDAQ: XFOR) commences equity offering; 30-day 15% option - Stock Titan hu, 23 Oct 2025 07
- X4 Pharmaceuticals Stock (XFOR) Opinions on $60M Financing and Leadership Shake-Up - Quiver Quantitative Wed, 13 Aug 2025 07
- X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval - Seeking Alpha ue, 03 Mar 2026 15
- Guggenheim Initiates Coverage on XFOR with a "Buy" Rating and $1 - GuruFocus Mon, 09 Mar 2026 14
- X4 Pharmaceuticals Expands Private Placement to $85M for Rare Disease Drug Development - Stock Titan Wed, 13 Aug 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 86206 | 249997.0 | — | Purchase at price 2.90 per share. | CRAIG ADAM R | Officer and Director | — | 2025-10-23 00:00:00 | D |
| 1 | 289881 | — | — | Stock Award(Grant) at price 0.00 per share. | CRAIG ADAM R | Officer and Director | — | 2025-08-14 00:00:00 | D |
| 2 | 193254 | — | — | Stock Award(Grant) at price 0.00 per share. | KIRSKE DAVID H. SR | Chief Financial Officer | — | 2025-08-14 00:00:00 | D |
| 3 | 289881 | — | — | Stock Award(Grant) at price 0.00 per share. | VOLPONE JOHN | President | — | 2025-08-14 00:00:00 | D |
| 4 | 1500 | — | — | Stock Award(Grant) at price 0.00 per share. | WYZGA MICHAEL S | Director | — | 2025-06-09 00:00:00 | D |
| 5 | 1500 | — | — | Stock Award(Grant) at price 0.00 per share. | MCGIRR DAVID W J | Director | — | 2025-06-09 00:00:00 | D |
| 6 | 1500 | — | — | Stock Award(Grant) at price 0.00 per share. | STEWART MURRAY | Director | — | 2025-06-09 00:00:00 | D |
| 7 | 1500 | — | — | Stock Award(Grant) at price 0.00 per share. | BRIDGER GARY J | Director | — | 2025-06-09 00:00:00 | D |
| 8 | 1500 | — | — | Stock Award(Grant) at price 0.00 per share. | DE CRAECKER FRANCOISE | Director | — | 2025-06-09 00:00:00 | D |
| 9 | 1500 | — | — | Stock Award(Grant) at price 0.00 per share. | WOODS KEITH | Director | — | 2025-06-09 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 22.45M | 1.49M | 464.10K | -2.73M |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -134.50M | -101.97M | -91.54M | -74.41M |
| TotalUnusualItems | 106.93M | 7.07M | 2.21M | -10.12M |
| TotalUnusualItemsExcludingGoodwill | 106.93M | 7.07M | 2.21M | -10.12M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -37.45M | -101.17M | -93.87M | -88.70M |
| ReconciledDepreciation | 796.00K | 419.00K | 513.00K | 499.00K |
| ReconciledCostOfRevenue | 797.00K | 0.00 | 0.00 | |
| EBITDA | -27.58M | -94.89M | -89.33M | -84.54M |
| EBIT | -28.37M | -95.31M | -89.85M | -85.04M |
| NetInterestIncome | -3.00M | -1.20M | -3.77M | -3.63M |
| InterestExpense | 8.77M | 5.78M | 3.99M | 3.64M |
| InterestIncome | 5.77M | 4.58M | 219.00K | 10.00K |
| NormalizedIncome | -121.92M | -106.76M | -95.61M | -81.31M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -37.45M | -101.17M | -93.87M | -88.70M |
| TotalExpenses | 143.96M | 107.52M | 88.08M | 75.35M |
| TotalOperatingIncomeAsReported | -36.40M | -107.52M | -87.57M | -85.11M |
| DilutedAverageShares | 6.70M | 5.93M | 2.12M | 858.30K |
| BasicAverageShares | 6.70M | 5.93M | 2.12M | 858.30K |
| DilutedEPS | -5.70 | -17.10 | -45.60 | -119.70 |
| BasicEPS | -5.70 | -17.10 | -45.60 | -119.70 |
| DilutedNIAvailtoComStockholders | -37.45M | -101.17M | -96.41M | -102.64M |
| NetIncomeCommonStockholders | -37.45M | -101.17M | -96.41M | -102.64M |
| OtherunderPreferredStockDividend | 0.00 | 0.00 | 2.55M | 13.94M |
| NetIncome | -37.45M | -101.17M | -93.87M | -88.70M |
| NetIncomeIncludingNoncontrollingInterests | -37.45M | -101.17M | -93.87M | -88.70M |
| NetIncomeContinuousOperations | -37.45M | -101.17M | -93.87M | -88.70M |
| TaxProvision | 310.00K | 78.00K | 28.00K | 17.00K |
| PretaxIncome | -37.14M | -101.09M | -93.84M | -88.68M |
| OtherIncomeExpense | 107.26M | 7.63M | -1.99M | -9.70M |
| OtherNonOperatingIncomeExpenses | 332.00K | 554.00K | -4.20M | 426.00K |
| SpecialIncomeCharges | 105.00M | 0.00 | 509.00K | -9.76M |
| GainOnSaleOfPPE | 105.00M | 0.00 | 509.00K | 0.00 |
| ImpairmentOfCapitalAssets | 0.00 | 0.00 | 9.76M | |
| GainOnSaleOfSecurity | 1.93M | 7.07M | 1.70M | -366.00K |
| NetNonOperatingInterestIncomeExpense | -3.00M | -1.20M | -3.77M | -3.63M |
| InterestExpenseNonOperating | 8.77M | 5.78M | 3.99M | 3.64M |
| InterestIncomeNonOperating | 5.77M | 4.58M | 219.00K | 10.00K |
| OperatingIncome | -141.40M | -107.52M | -88.08M | -75.35M |
| OperatingExpense | 143.16M | 107.52M | 88.08M | 75.35M |
| ResearchAndDevelopment | 81.64M | 72.02M | 61.06M | 50.65M |
| SellingGeneralAndAdministration | 61.52M | 35.51M | 27.02M | 24.70M |
| GeneralAndAdministrativeExpense | 24.70M | |||
| OtherGandA | 24.70M | |||
| GrossProfit | 1.76M | 0.00 | 0.00 | |
| CostOfRevenue | 797.00K | 0.00 | 0.00 | |
| TotalRevenue | 2.56M | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 2.56M | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 5.70M | 5.58M | 4.06M | 937.59K |
| ShareIssued | 5.70M | 5.58M | 4.06M | 937.59K |
| NetDebt | 19.73M | |||
| TotalDebt | 78.09M | 58.28M | 38.42M | 39.78M |
| TangibleBookValue | -5.20M | 33.75M | 56.70M | 47.06M |
| InvestedCapital | 97.57M | 105.67M | 107.67M | 98.35M |
| WorkingCapital | 79.30M | 99.21M | 106.35M | 73.86M |
| NetTangibleAssets | -5.20M | 33.75M | 56.70M | 47.06M |
| CapitalLeaseObligations | 2.66M | 3.71M | 4.80M | 5.85M |
| CommonStockEquity | 22.15M | 51.10M | 74.05M | 64.41M |
| TotalCapitalization | 97.57M | 105.67M | 106.36M | 97.55M |
| TotalEquityGrossMinorityInterest | 22.15M | 51.10M | 74.05M | 64.41M |
| StockholdersEquity | 22.15M | 51.10M | 74.05M | 64.41M |
| GainsLossesNotAffectingRetainedEarnings | -122.00K | -119.00K | -119.00K | -119.00K |
| OtherEquityAdjustments | -122.00K | -119.00K | -119.00K | -119.00K |
| RetainedEarnings | -515.36M | -477.90M | -376.74M | -282.87M |
| AdditionalPaidInCapital | 537.46M | 528.96M | 450.79M | 347.37M |
| CapitalStock | 171.00K | 167.00K | 122.00K | 28.00K |
| CommonStock | 171.00K | 167.00K | 122.00K | 28.00K |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 124.30M | 96.16M | 81.53M | 52.76M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 91.42M | 73.30M | 59.21M | 38.74M |
| OtherNonCurrentLiabilities | 831.00K | 432.00K | 173.00K | 826.00K |
| DerivativeProductLiabilities | 13.76M | 15.68M | 23.13M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 76.83M | 57.18M | 35.91M | 37.91M |
| LongTermCapitalLeaseObligation | 1.41M | 2.61M | 3.60M | 4.78M |
| LongTermDebt | 75.42M | 54.57M | 32.30M | 33.14M |
| CurrentLiabilities | 32.88M | 22.86M | 22.32M | 14.02M |
| CurrentDebtAndCapitalLeaseObligation | 1.25M | 1.10M | 2.51M | 1.87M |
| CurrentCapitalLeaseObligation | 1.25M | 1.10M | 1.20M | 1.07M |
| CurrentDebt | 1.31M | 795.00K | ||
| OtherCurrentBorrowings | 1.31M | 795.00K | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 13.05M | 8.20M | 6.59M | 5.42M |
| PayablesAndAccruedExpenses | 18.57M | 13.57M | 13.22M | 6.74M |
| CurrentAccruedExpenses | 9.95M | 4.62M | 5.44M | 2.45M |
| Payables | 8.62M | 8.95M | 7.78M | 4.28M |
| AccountsPayable | 8.62M | 8.95M | 7.78M | 4.28M |
| TotalAssets | 146.45M | 147.26M | 155.59M | 117.18M |
| TotalNonCurrentAssets | 34.27M | 25.18M | 26.91M | 29.30M |
| OtherNonCurrentAssets | 2.08M | 1.44M | 1.23M | 1.72M |
| GoodwillAndOtherIntangibleAssets | 27.35M | 17.35M | 17.35M | 17.35M |
| OtherIntangibleAssets | 10.00M | |||
| Goodwill | 17.35M | 17.35M | 17.35M | 17.35M |
| NetPPE | 4.84M | 6.39M | 8.33M | 10.22M |
| AccumulatedDepreciation | -1.90M | -1.62M | -1.23M | -724.00K |
| GrossPPE | 6.74M | 8.01M | 9.56M | 10.95M |
| Leases | 228.00K | 228.00K | 228.00K | 228.00K |
| OtherProperties | 4.73M | 6.30M | 7.87M | 9.29M |
| MachineryFurnitureEquipment | 1.78M | 1.49M | 1.47M | 1.43M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 112.17M | 122.08M | 128.68M | 87.88M |
| OtherCurrentAssets | 5.59M | 7.30M | 5.81M | 5.34M |
| PrepaidAssets | 5.34M | |||
| Inventory | 2.82M | 0.00 | ||
| FinishedGoods | 680.00K | 0.00 | ||
| WorkInProcess | 608.00K | 0.00 | ||
| RawMaterials | 1.53M | 0.00 | ||
| Receivables | 1.71M | 562.00K | 1.15M | 747.00K |
| OtherReceivables | 640.00K | 562.00K | 1.15M | 747.00K |
| AccountsReceivable | 1.07M | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 102.06M | 114.22M | 121.72M | 81.79M |
| OtherShortTermInvestments | 46.36M | 15.00M | 0.00 | |
| CashAndCashEquivalents | 55.70M | 99.22M | 121.72M | 81.79M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -138.23M | -96.57M | -77.20M | -71.52M |
| RepurchaseOfCapitalStock | 0.00 | 0.00 | -2.00M | |
| RepaymentOfDebt | 0.00 | -2.06M | -795.00K | 0.00 |
| IssuanceOfDebt | 20.00M | 22.50M | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 0.00 | 60.00M | 122.63M | 75.98M |
| CapitalExpenditure | -7.33M | -60.00K | -103.00K | -615.00K |
| InterestPaidSupplementalData | 7.77M | 4.60M | 3.01M | 2.91M |
| EndCashPosition | 56.48M | 100.25M | 123.03M | 83.11M |
| BeginningCashPosition | 100.25M | 123.03M | 83.11M | 80.70M |
| EffectOfExchangeRateChanges | -156.00K | 99.00K | -105.00K | -319.00K |
| ChangesInCash | -43.62M | -22.88M | 40.02M | 2.73M |
| FinancingCashFlow | 20.29M | 88.52M | 117.23M | 74.25M |
| CashFlowFromContinuingFinancingActivities | 20.29M | 88.52M | 117.23M | 74.25M |
| NetOtherFinancingCharges | -631.00K | -4.81M | ||
| ProceedsFromStockOptionExercised | 294.00K | 8.71M | 208.00K | 260.00K |
| NetCommonStockIssuance | 0.00 | 60.00M | 122.63M | 73.98M |
| CommonStockPayments | 0.00 | 0.00 | -2.00M | |
| CommonStockIssuance | 0.00 | 60.00M | 122.63M | 75.98M |
| NetIssuancePaymentsOfDebt | 20.00M | 20.44M | -795.00K | 0.00 |
| NetLongTermDebtIssuance | 20.00M | 20.44M | -795.00K | 0.00 |
| LongTermDebtPayments | 0.00 | -2.06M | -795.00K | 0.00 |
| LongTermDebtIssuance | 20.00M | 22.50M | 0.00 | 0.00 |
| InvestingCashFlow | 66.99M | -14.88M | -103.00K | -615.00K |
| CashFlowFromContinuingInvestingActivities | 66.99M | -14.88M | -103.00K | -615.00K |
| NetOtherInvestingChanges | 105.00M | |||
| NetInvestmentPurchaseAndSale | -30.68M | -14.82M | 0.00 | 0.00 |
| SaleOfInvestment | 26.45M | 2.00M | 0.00 | 0.00 |
| PurchaseOfInvestment | -57.13M | -16.82M | 0.00 | 0.00 |
| NetIntangiblesPurchaseAndSale | -7.00M | 0.00 | 0.00 | |
| PurchaseOfIntangibles | -7.00M | 0.00 | 0.00 | |
| NetPPEPurchaseAndSale | -326.00K | -60.00K | -103.00K | -615.00K |
| PurchaseOfPPE | -326.00K | -60.00K | -103.00K | -615.00K |
| OperatingCashFlow | -130.90M | -96.51M | -77.10M | -70.91M |
| CashFlowFromContinuingOperatingActivities | -130.90M | -96.51M | -77.10M | -70.91M |
| ChangeInWorkingCapital | 2.67M | 344.00K | 5.74M | -1.50M |
| ChangeInOtherCurrentLiabilities | -1.00M | -1.13M | -882.00K | -698.00K |
| ChangeInOtherCurrentAssets | 0.00 | 0.00 | -59.00K | |
| ChangeInPayablesAndAccruedExpense | 6.88M | 2.84M | 7.23M | 1.01M |
| ChangeInAccruedExpense | 7.17M | 1.61M | 3.80M | -152.00K |
| ChangeInPayable | -286.00K | 1.23M | 3.42M | 1.17M |
| ChangeInAccountPayable | -286.00K | 1.23M | 3.42M | 1.17M |
| ChangeInPrepaidAssets | 683.00K | -1.37M | -610.00K | -1.75M |
| ChangeInInventory | -2.82M | 0.00 | 0.00 | |
| ChangeInReceivables | -1.07M | 0.00 | 0.00 | |
| ChangesInAccountReceivables | -1.07M | 0.00 | 0.00 | |
| OtherNonCashItems | 1.80M | 2.28M | 2.44M | 2.49M |
| StockBasedCompensation | 8.20M | 8.69M | 5.20M | 6.18M |
| AssetImpairmentCharge | 0.00 | 0.00 | 9.76M | |
| DepreciationAmortizationDepletion | 796.00K | 419.00K | 513.00K | 499.00K |
| DepreciationAndAmortization | 796.00K | 419.00K | 513.00K | 499.00K |
| OperatingGainsLosses | -106.93M | -7.07M | 2.88M | 366.00K |
| GainLossOnInvestmentSecurities | -1.93M | -7.07M | 2.88M | 366.00K |
| NetIncomeFromContinuingOperations | -37.45M | -101.17M | -93.87M | -88.70M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for XFOR
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|